| Inclusion Criteria: | 1) Women with platinum-resistant, histologically confirmed epithelial ovarian, fallopian tube or peritoneal cancer. Resistance is defined as: Progression of disease during platinum chemotherapy, or progression of disease within 6 months of completing platinum chemotherapy, or failure to achieve a complete response, with persistent macroscopic disease, after an adequate trial of primary therapy.
2) EGF-R expression must be positive (e.g., 1+ or greater) See appendix G.
3) Patients with a known hypersensitivity to platinum compounds, who have failed a desensitization regimen, or in the opinion of the investigator, are not good candidates for desensitization, are eligible.
4) Patients must have measurable disease.
5) Unlimited number of prior chemotherapy regimens are allowed.
6) Zubrod performance status </= 2.
7) Patients must have adequate hepatic, renal, and bone marrow function, defined as serum creatinine </= 2 mg/dl (estimated creatinine clearance 50 ml/min); total bilirubin < /=2.0 X the upper limit of normal (ULN); alanine aminotransferase (ALT) </= 2X ULN; white blood count (WBC) >/= 3,000/mm3; absolute neutrophil count (ANC) >/= 1,500/mm3; platelets >/= 100,000/mm3.
8) At least three weeks must have elapsed from completion of chemotherapy or radiation therapy.
9) At least 30 days must have elapsed from completion of treatment with a non-approved or investigational drug.
10) Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the hospital. The only approved consent is appended to this protocol.
11) Women of childbearing potential must be willing to practice acceptable methods of birth control to prevent pregnancy. |